Impact of cytotoxic chemotherapy on aldo-keto reductase family 1 member B10 expression.

Autor:	Robinson K; Simmons Cancer Institute, Southern Illinois University, Springfield, IL, USA., Cao Z; Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Delfino K; Center for Clinical Research, Southern Illinois University, Springfield, IL, USA., Cao D; Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Rao K; Division of Hematology/Oncology, Simmons Cancer Institute, Southern Illinois University, Springfield, IL, USA.
Jazyk:	angličtina
Zdroj:	The Journal of international medical research [J Int Med Res] 2023 Jun; Vol. 51 (6), pp. 3000605231179317.
DOI:	10.1177/03000605231179317
Abstrakt:	Objective: Aldo-keto reductase family 1 member B10 (AKR1B10) is a protein that is produced and secreted by a significant number of breast cancers. However, a potential confounder to the use of AKR1B10 as a tumor marker is its elevation in patients given cytotoxic chemotherapy. We therefore conducted a prospective study to analyze AKR1B10 levels in patients with breast cancer receiving neoadjuvant cytotoxic chemotherapy. Methods: The study enrolled 10 patients from November 2015 to July 2017. All patients had locally advanced, but non-metastatic, breast cancer, and they received neoadjuvant chemotherapy followed by surgery. Serum AKR1B10 levels and tumor imaging were assessed before, during, and after chemotherapy. Results: No increase in serum AKR1B10 levels was noted in patients receiving chemotherapy whose levels were elevated at diagnosis. Conclusion: The findings are complex, but the overall data suggest that AKR1B10 is suitable as a tumor marker in patients with elevated levels at the time of diagnosis.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu